Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States
A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the tolerability and dose modifications of PARP inhibitor therapies for ovarian cancer in the United States.
Pembrolizumab and Lenvatinib Use for Endometrial Cancer in Clinical Practice
Study results support a lower starting dose of lenvatinib in clinical practice than what is currently recommended by the FDA.
Out-of-Pocket Cost-Effectiveness of Frontline Maintenance Strategies for Advanced Ovarian Cancer
In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is cost-effective for commercially insured patients with advanced ovarian cancer, but not those covered under Medicare.
Minimally Invasive Surgery Cost-Effective vs Laparotomy for Early-Stage Ovarian Cancer
Minimally invasive surgery is cost-effective compared with laparotomy for suspicious ovarian masses, even though it is associated with increased risk of capsule rupture and death from ovarian cancer.
